Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients

Haematologica

Volumn 92, Issue 9, 2007, Pages 1289-1290

  Petrucci, Maria Teresa ^a   Gallucci, Cristiano ^a   Agrillo, Alessandro ^a   Mustazza, Maria Cristina ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bisphosphonates; Multiple myeloma; Osteonecrosis of the jaw; Ozone therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; METRONIDAZOLE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE NECROSIS; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DENTAL CARE; DRUG EFFICACY; FEMALE; HUMAN; JAW DISEASE; JAW RADIOGRAPHY; MALE; MAXILLA; MOUTH HYGIENE; MULTIPLE MYELOMA; OZONE THERAPY; QUESTIONNAIRE; SCORING SYSTEM; TOOTH EXTRACTION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; DIPHOSPHONATES; HUMANS; JAW DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OZONE;

EID: 36348948530     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11096     Document Type: Article

References (10)

1. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6.
2. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
3. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
4. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
5. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134:620-3.
6. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91:968-71.
7. Migliorati CA, Schubert MM, Peterson DE, Senada LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
8. Stubinger S, Sader R, Filippi A. The use of ozone in dentistry and maxillofacial surgery: a review. Quintessence Int 2006;37:353-9.
9. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
10. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Eng J Med 2005;353:99-102.